Search research articles
Contact Us
Filters
Showing results (141-150 of 635) with videos related to
Page
of 64
Sort By:
The American Journal of Cardiology
|
April 2, 2017
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II])
Benjamin A Steinberg, DaJuanicia N Simon, Laine Thomas, et al.
Journal of Thrombosis and Thrombolysis
|
February 11, 2012
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin
Michael P Thomas, Kenneth W Mahaffey, Karen Chiswell, et al.
JACC. Heart Failure
|
November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
JingWei Li, Mark Woodward, Vlado Perkovic, et al.
International Journal of Cardiology
|
September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Jie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
Diabetes, Obesity & Metabolism
|
March 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE
Michael A Tsoukas, Vincent Woo, Sheldon W Tobe, et al.
Journal of Thrombosis and Thrombolysis
|
November 19, 2010
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome
Richard C Becker, Kenneth W Mahaffey, Hongqiu Yang, et al.
The American Journal of Cardiology
|
January 28, 2010
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI)
John K French, Anne S Hellkamp, Paul W Armstrong, et al.
Journal of the American Society of Nephrology : JASN
|
July 23, 2020
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
Megumi Oshima, Bruce Neal, Tadashi Toyama, et al.
American Heart Journal
|
July 31, 2013
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct
Renato D Lopes, Sheila Dickerson, Gail Hafley, et al.
Diabetes, Obesity & Metabolism
|
January 26, 2017
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial
Bruce Neal, Vlado Perkovic, David R Matthews, et al.
Page
of 64
Search research articles
Search
Showing results (141-150 of 635) with videos related to
Sort By:
Page
of 64
The American Journal of Cardiology
|
April 2, 2017
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II])
Benjamin A Steinberg, DaJuanicia N Simon, Laine Thomas, et al.
Journal of Thrombosis and Thrombolysis
|
February 11, 2012
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin
Michael P Thomas, Kenneth W Mahaffey, Karen Chiswell, et al.
JACC. Heart Failure
|
November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
JingWei Li, Mark Woodward, Vlado Perkovic, et al.
International Journal of Cardiology
|
September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Jie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
Diabetes, Obesity & Metabolism
|
March 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE
Michael A Tsoukas, Vincent Woo, Sheldon W Tobe, et al.
Journal of Thrombosis and Thrombolysis
|
November 19, 2010
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome
Richard C Becker, Kenneth W Mahaffey, Hongqiu Yang, et al.
The American Journal of Cardiology
|
January 28, 2010
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI)
John K French, Anne S Hellkamp, Paul W Armstrong, et al.
Journal of the American Society of Nephrology : JASN
|
July 23, 2020
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
Megumi Oshima, Bruce Neal, Tadashi Toyama, et al.
American Heart Journal
|
July 31, 2013
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct
Renato D Lopes, Sheila Dickerson, Gail Hafley, et al.
Diabetes, Obesity & Metabolism
|
January 26, 2017
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial
Bruce Neal, Vlado Perkovic, David R Matthews, et al.
Page
of 64